The FDA has cleared Current Health’s wireless wearable remote patient monitoring (RPM) platform for chronically ill individuals, allowing care teams to track their patients’ health in real-time and act proactively when something looks off.
Current’s wearable, a palm-sized, AI-powered device worn on a person’s upper arm, was granted Class II clearance by the FDA April 24 for post-acute care and is now available for both hospital and at-home use. The company claims its monitor provides ICU-level accuracy and tracks more vital signs than any other all-in-one wearable on the market.
“Our rapidly growing customer base indicates how focused health systems and home health agencies are on moving more healthcare from hospital to home,” Current Health CEO and co-founder Christopher McCann said in a statement. “Today, Current is helping them do just that by monitoring patients’ health trajectories to enable earlier interventions, reduce the overall and growing cost of hospital readmissions and, more importantly, prevent avoidable deaths.
“But more fundamentally, we’re building a future where healthcare comes to us. Patients don’t always know when their to call their doctor. Current will.”
Current has partnered with six of the largest health systems in the U.S., including Mount Sinai, and a handful of U.K. NHS Trusts to help providers track at-risk patients’ health after they leave the hospital. The company said traditional RPM and telehealth solutions don’t perform as well as the Current device and are bogged down with manual data entry, unreliable measurements and low patient uptake.
On the other hand, Current’s RPM and telehealth platform includes Bluetooth integrations with other health devices and provides patients with a tablet equipped with a chatbot for Q&A, medication reminders and educational content.
The company said it hopes FDA clearance will pave the way for more care providers to integrate Current’s platform into their own workflow, reducing hospital readmissions, decreasing lengths of stay and allowing physicians a chance to intervene before it’s too late.